Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-duration fidaxomicin versus vancomycin in older adults with Clostridium difficile infection
2013-004619-31Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2014
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Clostridioides difficile colitis (CDI) comparing Extended-duration fidaxomicin with Standard vancomycin therapy (2 arms). Primary endpoint: Sustained clinical cure of Clostridium difficile infection. Started Jul 2014; status: completed.
02
Drugs
fidaxomicinvancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2013-004619-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004619-31.